Found: 6
Select item for more details and to access through your institution.
PAX2 Expression in Ovarian Cancer.
- Published in:
- International Journal of Molecular Sciences, 2013, v. 14, n. 3, p. 6090, doi. 10.3390/ijms14036090
- By:
- Publication type:
- Article
Structure-guided chemical modification of guide RNA enables potent non-viral in vivo genome editing.
- Published in:
- Nature Biotechnology, 2017, v. 35, n. 12, p. 1179, doi. 10.1038/nbt.4005
- By:
- Publication type:
- Article
KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma.
- Published in:
- Journal of Pathology, 2013, v. 231, n. 4, p. 449, doi. 10.1002/path.4252
- By:
- Publication type:
- Article
Nutlin-3a: A Potential Therapeutic Opportunity for TP53 Wild-Type Ovarian Carcinomas.
- Published in:
- PLoS ONE, 2015, v. 10, n. 8, p. 1, doi. 10.1371/journal.pone.0135101
- By:
- Publication type:
- Article
The Role of GDF15 in Regulating the Canonical Pathways of the Tumor Microenvironment in Wild-Type p53 Ovarian Tumor and Its Response to Chemotherapy.
- Published in:
- Cancers, 2020, v. 12, n. 10, p. 3043, doi. 10.3390/cancers12103043
- By:
- Publication type:
- Article
CRISPR-SONIC: targeted somatic oncogene knock-in enables rapid in vivo cancer modeling.
- Published in:
- Genome Medicine, 2019, v. 11, n. 1, p. N.PAG, doi. 10.1186/s13073-019-0627-9
- By:
- Publication type:
- Article